A phase I/II study of C019199 in combination with sintilimab in advanced malignancy. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text ...
A new research paper was published in Volume 17 of Oncotarget on June 3, 2026, titled "The anticancer effects of PCAIs in ...
Anti-tumor activity of BH-30643, a novel macrocyclic kinase inhibitor, in EGFR-mutant lung cancer models. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...
Figure 10: Biochemical effects of PCAIs on cancer cells. PCAIs-treated cancer cells show the depletion of the monomeric G-proteins RAC1 and RHOA. MAPK and PI3K/AKT signaling pathways are activated ...
PAS-004 is being tested in a phase 1 trial for MAPK pathway-driven advanced solid tumors, with dosing initiated at 30 mg. The trial is multicenter, open-label, and dose-escalation, assessing safety, ...
Signal transduction The cellular process that converts a signal, such as a hormone, growth factor, neurotransmitter, cytokine, mechanical force, or environmental cue, into biochemical changes inside ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results